Abeona Therapeutics (NASDAQ:ABEO) Given Media Impact Score of 0.10

Media stories about Abeona Therapeutics (NASDAQ:ABEO) have trended somewhat positive on Friday, according to Accern Sentiment. The research firm rates the sentiment of news coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Abeona Therapeutics earned a media sentiment score of 0.10 on Accern’s scale. Accern also assigned media stories about the biopharmaceutical company an impact score of 47.883936106746 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

A number of research analysts recently weighed in on ABEO shares. Zacks Investment Research cut shares of Abeona Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, November 23rd. SunTrust Banks started coverage on shares of Abeona Therapeutics in a report on Wednesday, November 8th. They issued a “buy” rating and a $26.00 price objective for the company. Cantor Fitzgerald restated a “buy” rating and issued a $21.00 price objective on shares of Abeona Therapeutics in a report on Friday, October 6th. Citigroup started coverage on shares of Abeona Therapeutics in a report on Tuesday, October 10th. They issued a “buy” rating and a $32.00 price objective for the company. Finally, Jefferies Group restated a “buy” rating and issued a $28.00 price objective on shares of Abeona Therapeutics in a report on Wednesday, November 22nd. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and nine have assigned a buy rating to the stock. Abeona Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $26.10.

Abeona Therapeutics (NASDAQ:ABEO) opened at $15.85 on Friday. Abeona Therapeutics has a 12 month low of $4.50 and a 12 month high of $22.75. The stock has a market cap of $741.39, a P/E ratio of -24.38 and a beta of 2.34.

Abeona Therapeutics (NASDAQ:ABEO) last issued its quarterly earnings results on Wednesday, November 15th. The biopharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.05. Abeona Therapeutics had a negative net margin of 2,439.73% and a negative return on equity of 23.95%. The company had revenue of $0.22 million during the quarter, compared to the consensus estimate of $0.22 million. analysts expect that Abeona Therapeutics will post -0.6 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Abeona Therapeutics (NASDAQ:ABEO) Given Media Impact Score of 0.10” was first posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of U.S. and international trademark and copyright law. The original version of this piece of content can be viewed at https://stocknewstimes.com/2018/01/12/somewhat-favorable-news-coverage-somewhat-unlikely-to-impact-abeona-therapeutics-abeo-share-price.html.

About Abeona Therapeutics

Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB).

Insider Buying and Selling by Quarter for Abeona Therapeutics (NASDAQ:ABEO)

Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply